Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Alkeus Pharmaceuticals has raised $150 million via a Series B round in order to advance a precision medicine candidate to treat Stargardt disease, a currently …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Bain leads $150M round to push blind­ness biotech's rare dis­ease drug to­ward FDA

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Roivant brings rare disease program closer as Immunovant CEO retires

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence